Development and clinical application of an enzyme immunoassay for the determination of midregional proadrenomedullin

Journal of Peptide Science

Volumn 19, Issue 1, 2013, Pages 59-63

  Suzuki, Yosuke ^a   Itoh, Hiroki ^a   Katagiri, Fumihiko ^b   Sato, Fuminori ^c   Sato, Yukie ^a   Kawasaki, Kanako ^a   Sato, Yuhki ^a   Mimata, Hiromitsu ^c   Takeyama, Masaharu ^a  

^a OITA UNIVERSITY HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

ADM; Adrenomedullin; Clinical application; Enzyme immunoassay; Midregional proadrenomedullin; MR proADM

Indexed keywords

BETA GALACTOSIDASE; PROADRENOMEDULLIN;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LIMIT OF QUANTITATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADRENOMEDULLIN; ADULT; AMINO ACID SEQUENCE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY FAILURE, CHRONIC; MALE; MOLECULAR SEQUENCE DATA; PROTEIN PRECURSORS;

ORYCTOLAGUS CUNICULUS;

EID: 84871661835     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2473     Document Type: Article

References (26)

1. Linscheid P, Seboek D, Zulewski H, Keller U, Müller B. Autocrine/ paracrine role of inflammation-mediated calcitonin gene related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005; 146: 2699-2708.
2. Pio R, Martinez A, Unsworth EJ, Kowalak JA, Bengoechea JA, Zipfel PF, Elsasser TH, Cuttitta F. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J. Biol. Chem. 2001; 276: 12292-12300.
3. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr. Med. Chem. 2007; 14: 1689-1699.
4. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 1993; 192: 553-560.
5. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr. Rev. 2000; 21: 138-167.
6. Kobayashi K, Kitamura K, Etoh T, Nagatomo Y, Takenaga M, Ishikawa T, Imamura T, Koiwaya Y, Eto T. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am. Heart J. 1996; 131: 994-998.
7. Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, Marumo F. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J. Clin. Endocrinol. Metab. 1996; 81: 1449-1453.
8. Meeran K, O'Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH, Bloom SR. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J. Clin. Endocrinol. Metab. 1997; 82: 95-100.
9. Kitamura K, Kangawa K, Ishiyama Y, Washimine H, Ichiki Y, Kawamoto M, Minamino N, Matsuo H, Eto T. Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP). FEBS Lett. 1994; 351: 35-37.
10. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004; 25: 1369-1372.
11. Gumusel B, Chang JK, Hyman A, Lippton H. Adrenotensin: an ADM gene product with the opposite effects of ADM. Life Sci. 1995; 57: PL87-90.
12. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit. Care 2005; 9: R816-824.
13. Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohé J, Lepape A, Monneret G. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med. 2009; 35: 1859-1867.
14. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, Delude RL, Rosengart MR, Yealy DM. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136: 823-831.
15. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am. J. Respir. Crit. Care Med. 2010; 182: 1426-1434.
16. Albrich WC, Dusemund F, Rüegger K, Christ-Crain M, Zimmerli W, Bregenzer T, Irani S, Buergi U, Reutlinger B, Mueller B, Schuetz P. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect. Dis. 2011; 11: 112.
17. Adlbrecht C, Hülsmann M, Strunk G, Berger R, Mörtl D, Struck J, Morgenthaler NG, Bergmann A, Jakowitsch J, Maurer G, Lang IM, Pacher R. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur. J. Heart Fail. 2009; 11: 361-366.
18. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, Rozentryt P, Vassanelli C, Struck J, Banasiak W, Ponikowski P, Kremastinos D, Bergmann A, Morgenthaler NG, Anker SD. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur. J. Heart Fail. 2010; 12: 484-91.
19. Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Hartmann O, Morgenthaler NG, Anker SD. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J. Am. Coll. Cardiol. 2011; 58: 1057-1067.
20. Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, Haltmayer M, Kronenberg F, MMKD Study Group. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int. 2009; 75: 408-414.
21. Gouya G, Sturm G, Lamina C, Zitt E, Freistätter O, Struck J, Wolzt M, Knoll F, Lins F, Lhotta K, Neyer U, Kronenberg F. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. PLoS One 2011; 6: e17803.
22. Yoshihara F, Ernst A, Morgenthaler NG, Horio T, Nakamura S, Nakahama H, Nakata H, Bergmann A, Kangawa K, Kawano Y. Midregional proadrenomedullin reflects cardiac dysfunction in haemodialysis patients with cardiovascular disease. Nephrol. Dial. Transplant. 2007; 22: 2263-2268.
23. Suzuki Y, Itoh H, Katagiri F, Sato F, Kawasaki K, Sato Y, Mimata H, Takeyama M. Establishment and clinical application of a highly sensitive enzyme immunoassay for determination of N-acetyl-seryl-aspartyl-lysyl-proline. J. Pept. Sci. 2012; 18: 276-281.
24. Tai HH, Chey WY. Development of radioimmunoassay for motilin. Anal. Biochem. 1978; 87: 350-358.
25. Kitagawa T, Shimozono T, Aikawa T, Yoshida T, Nishimura H. Preparation and characterization of hetero-bifunctional cross-linking reagents for protein modifications. Chem. Pharm. Bull. 1981; 29: 1130-1135.
26. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin. Chem. 2005; 51: 1823-1829.